ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0764 • ACR Convergence 2022

    No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors

    Tawnie Braaten1, Brian Sauer2, Gary Kunkel3, Jessica Walsh3, Jorge Rojas4, Bryant England5, Joshua Baker6 and Grant Cannon7, 1University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT, 4George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, 5University of Nebraska Medical Center, Omaha, NE, 6University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 7Salt Lake City VA, Salt Lake city

    Background/Purpose: Immune checkpoint inhibitor (ICI) use for the treatment of multiple cancers continues to expand. Data on ICI treatment in autoimmune disease is limited as…
  • Abstract Number: 0831 • ACR Convergence 2022

    Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital

    Kinza Muzaffar1, Sulman Hasan2, Sarwat umer2, Mohammad Alfrad Nobel Bhuiyan2, Kavya Vadlamudi2, Manush Sondhi2, Anusheh Ali1, Tabitha Muutu2 and Samina Hayat1, 1Louisiana State University, Shreveport, LA, 2LSU Health Shreveport, Shreveport, LA

    Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…
  • Abstract Number: 1114 • ACR Convergence 2022

    Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis

    Dillon Popovich1, Noelle Kosarek2, Rezvan Parvizi3, Tamar Abel4, Mengqi Huang5, Monica Espinoza6, Avi Smith7, Sasha Shenk7, Jonathan Garlick7 and Michael Whitfield8, 1Dartmouth College, West Lebanon, NH, 2Dartmouth Geisel School of Medicine, Lebanon, NH, 3Dartmouth, Lebanon, NH, 4Dartmouth College, Lebanon, NH, 5University of Pittsburgh, Pittsburgh, PN, 6Dartmouth College, Hanover, NH, 7Tufts University School of Dental Medicine, Boston, MA, 8Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Genome-wide analyses of gene expression in systemic sclerosis (SSc) skin biopsies have identified differential responses based on the mechanism of action of the therapy.…
  • Abstract Number: 1287 • ACR Convergence 2022

    Are the American College of Rheumatology’s Web-Based Patient Education Materials Easy for Patients to Read and Comprehend?

    Ugochukwu C Nweke1, Sobia Hassan2, Usama Ahmad3 and Meenakshi Jolly4, 1Rush University,Graduate College, Chicago, IL, 2Rush University Medical Center, Chicago,IL, Chicago, IL, 3Rush Univesity Medical Center, Chicago, IL, 4Rush University Medical Center, Chicago, IL

    Background/Purpose: Patient education materials (PEMs), obtainable from online resources, can be accessed by patients and physicians and used to supplement the medical information provided by…
  • Abstract Number: 1542 • ACR Convergence 2022

    Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry

    Shery Susan Philip1, Ramya Janardana1, Revanesh S Mirji1, Chengappa Kavadichanda2, Devender Bairwa3, Geetabali Sircar4, Parasar Ghosh5, Anupam Wakhlu6, Padmanabha Shenoy7, Sumithra Selvam8 and Vineeta Shobha1, 1St. John’s Medical College Hospital, Bangalore, India, 2JIPMER, Pondicherry, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, 4Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, 5Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 6Apollo Medics Super Speciality Hospitals, Lucknow, India, 7Centre for Arthritis and Rheumatism Excellence (CARE), Cochi, India, 8Division of Epidemiology and Biostatistics, St. John’s Research Institute, St. John's Medical College Hospital, Bangalore, India

    Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…
  • Abstract Number: 1742 • ACR Convergence 2022

    Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA

    Ravi Kumar1, Anatoly Dubnovitsky1, Christina Gerstner1, Niyaz Yoosuf2, Sara Turcinov1, Sanjay Boddul1, Fredrik Wermeling1, Lars Klareskog1, Leonid Padyukov1 and vivianne malmström1, 1Karolinska Institutet, Stockholm, Sweden, 2Bioinvent International AB, Lund, Sweden

    Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…
  • Abstract Number: 2040 • ACR Convergence 2022

    Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, R. Hal Scofield2, Kiely Grundahl1, Lida Radfar2, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
  • Abstract Number: 2274 • ACR Convergence 2022

    Factors Associated with Disease Flare Following SARS-CoV-2 Vaccination in People with Inflammatory Rheumatic and Musculoskeletal Diseases – Results from the Physician-Reported EULAR Coronavirus Vaccine (COVAX) Registry

    Bayram Farisoğulları1, Saskia Lawson-Tovey2, Kimme Hyrich3, Laure Gossec4, Loreto Carmona5, Anja Strangfeld6, Elsa Mateus7, Martin Schaefer8, Ana Maria Rodrigues9, Eric Hachulla10, Jose A Gomez-Puerta11, Marta Mosca12, Patrick Durez13, Ludovic Trefond14, Tiphaine Goulenok15, Martina Cornalba16, Emoke Šteňová17, Inita Bulina18, Eva Strakova19, Julija Zepa20, Nicolas Roux21, Olivier Brocq22, Viellard Eric23, Bernd Raffeiner24, Gerd Burmester25, Xavier Mariette26 and Pedro Machado27, 1Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey, 2Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3The University of Manchester, Manchester, United Kingdom, 4Sorbonne Université, Paris, France, 5Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, 6Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 7EULAR, Lisboa, Portugal, 8German Rheumatism Research Center, Berlin, Germany, 9Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, 10University of Lille, LILLE, France, 11Hospital Clínic de Barcelona, Barcelona, Spain, 12Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 13Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 14Université Clermont Auvergne, CHU Clermont-Ferrand, Service de Médecine Interne, Hôpital Gabriel Montpied, INSERM U1071, Clermont-Ferrand, France, 15APHP, Paris, France, 16Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Milano, Italy, 17University Hospital, Bratislava, Slovakia, 18Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, 19Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, 20Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, 21Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, 22Rheumatology- CH Princesse Grace, Monaco, Monaco, 23Private practice, St. Malo, France, 24Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, 25Charité University Medicine Berlin, Berlin, Germany, 26Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 27University College London, London, United Kingdom

    Background/Purpose: To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMD).Methods: The…
  • Abstract Number: 0132 • ACR Convergence 2022

    Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre

    Belén Atienza-Mateo1, Sara Remuzgo-Martinez1, Diego Ferrer2, Gerardo Blanco Rodríguez3, Sheila Izquierdo Cuervo2, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Ricardo Blanco4, José M. Cifrián1 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Department of Radiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease (ILD) that can be idiopathic or associated with a variety of different conditions, including connective…
  • Abstract Number: 0335 • ACR Convergence 2022

    Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile

    Mariko Ogawa-Momohara1, Thomas Vazquez2, Meena Sharma2, Josh Dan3, Grant Sprow3 and Victoria Werth3, 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

    Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…
  • Abstract Number: 0599 • ACR Convergence 2022

    Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis

    Christian Geier1, Andras Perl2 and Robert Winchester3, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY, Syracuse, NY, 3Columbia University, New York, NY

    Background/Purpose: In RA, aberrant lymphocytes can damage synovial joints and other organs. Antigen-presenting cells (APC) can activate lymphocytes and are considered critical to initiate immune…
  • Abstract Number: 0710 • ACR Convergence 2022

    Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study

    Naomi Patel1, Xiaosong Wang2, Xiaoqing Fu3, Yumeko Kawano2, Claire Cook3, Kathleen Vanni2, Grace Qian2, Emily Banasiak2, Emily Kowalski2, yuqing zhang4, Jeffrey Sparks5 and Zachary Wallace3, 1Massachusetts General Hospital, Sale Creek, TN, 2Brigham and Women's Hospital, Boston, MA, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital, Quincy, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Some patients with rheumatic disease on DMARDs may be at increased risk of poor response to SARS-CoV-2 vaccines and thus breakthrough COVID-19 infections. We…
  • Abstract Number: 0765 • ACR Convergence 2022

    The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)

    Martina Frodlund1, Katerina Chatzidionysiou2, Anna Södergren3, Eva Klingberg4, Anders A Bengtsson5, Monika Hansson2, Sophie Ohlsson6, Elisa Pin7, Lars Klareskog8 and Meliha Kapetanovic9, 1Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 2Department of Medicine, Solna, Division of Rheumatology, Karolinska University Hospital at Karolinska Institutet, Stockholm, Sweden, 3Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden and Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden, 4Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 5Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 6Department of Clinical Sciences, Lund, Section for Nephrology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 7Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden, 8Karolinska Institutet, Stockholm, Sweden, 9Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden

    Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…
  • Abstract Number: 0832 • ACR Convergence 2022

    Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?

    Paulo Vilas-Boas1, Gisela Eugenio2 and Anabela Barcelos2, 1Rheumatology Department, Centro Hospitalar Baixo Vouga, Aveiro, Portugal, 2Centro Hospitalar Baixo Vouga, Aveiro, Portugal

    Background/Purpose: Anti-NOR 90 antibodies have been detected in inflammatory conditions, neoplastic diseases and even in healthy individuals. Despite numerous epidemiologic studies, large scale studies are…
  • Abstract Number: 1121 • ACR Convergence 2022

    Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies

    Danlei Zhou1, Emily H King1, Simon Rothwell2, Olga Kryštůfková3, Antonella Notarnicola4, Samantha Coss1, Rabheh Abdul Aziz5, Katherine E Miller1, Amanda Dang1, G. Richard Yu1, Joanne Drew6, Emeli Lundstrom4, Lauren Pachman7, Gulnara Mamyrova8, Rodolfo V Curiel8, Boel De Paepe9, Jan De Bleecker9, Antony Payton10, William Ollier11, Terrance P O'Hanlon12, Ira Targoff12, Willy Flegel12, Vidya Sivaraman6, Edward Oberle6, Shoghik Akoghlanian6, Kyla Driest6, Charles H Spencer13, Yee Ling Wu14, Haikady N Nagaraja15, Stacy P Ardoin6, Hector Chinoy16, Lisa G Rider12, Frederick Miller12, Ingrid Lundberg17, Leonid Padyukov18, Jiří Vencovský3, Janine A Lamb2 and Chack-Yung Yu1, 1Center for Microbial Pathogenesis, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH, 2National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 6Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 7Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, 8Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, 9Department of Neurology, Ghent University Hospital, Ghent, Belgium, 10Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 11Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom, 12Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, 13Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, 14Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, 15Division of Biostatistics, The Ohio State University, Columbus, OH, 16The University of Manchester, Sale, United Kingdom, 17Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 18Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by autoantibodies plus infiltration of leukocytes into muscles and/or the skin, leading to…
  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology